These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 33401460)

  • 1. Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression.
    Armitage JD; Newnes HV; McDonnell A; Bosco A; Waithman J
    Cells; 2021 Jan; 10(1):. PubMed ID: 33401460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
    Finn OJ
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical role of the TME in solid cancer.
    Giraldo NA; Sanchez-Salas R; Peske JD; Vano Y; Becht E; Petitprez F; Validire P; Ingels A; Cathelineau X; Fridman WH; Sautès-Fridman C
    Br J Cancer; 2019 Jan; 120(1):45-53. PubMed ID: 30413828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
    Hofer F; Di Sario G; Musiu C; Sartoris S; De Sanctis F; Ugel S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
    O'Malley G; Heijltjes M; Houston AM; Rani S; Ritter T; Egan LJ; Ryan AE
    Oncotarget; 2016 Sep; 7(37):60752-60774. PubMed ID: 27542276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-Mediated Subversion of Anti-Tumour Immunity.
    Quaranta V; Schmid MC
    Cells; 2019 Jul; 8(7):. PubMed ID: 31331034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal Molecular Imaging of the Tumour Microenvironment.
    Foray C; Barca C; Backhaus P; Schelhaas S; Winkeler A; Viel T; Schäfers M; Grauer O; Jacobs AH; Zinnhardt B
    Adv Exp Med Biol; 2020; 1225():71-87. PubMed ID: 32030648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment.
    Newnes HV; Armitage JD; Audsley KM; Bosco A; Waithman J
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
    Eskandari-Malayeri F; Rezaei M
    Front Immunol; 2022; 13():996145. PubMed ID: 36275750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
    Hofman L; Lawler SE; Lamfers MLM
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
    Sun B; Hyun H; Li LT; Wang AZ
    Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanoimmunology in the solid tumor microenvironment.
    Golo M; Newman PLH; Kempe D; Biro M
    Biochem Soc Trans; 2024 Jun; 52(3):1489-1502. PubMed ID: 38856041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
    Buoncervello M; Gabriele L; Toschi E
    Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy.
    Fu Z; Mowday AM; Smaill JB; Hermans IF; Patterson AV
    Cells; 2021 Apr; 10(5):. PubMed ID: 33923305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of regulatory T cells in cancer immunology and immunotherapy.
    Sugiyama D; Hinohara K; Nishikawa H
    Exp Dermatol; 2023 Mar; 32(3):256-263. PubMed ID: 36458459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil diversity and plasticity in tumour progression and therapy.
    Jaillon S; Ponzetta A; Di Mitri D; Santoni A; Bonecchi R; Mantovani A
    Nat Rev Cancer; 2020 Sep; 20(9):485-503. PubMed ID: 32694624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy.
    Wu Q; Mao H; Jiang Z; Tang D
    Immunology; 2024 Jul; 172(3):343-361. PubMed ID: 38402904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.